Thymosin Alpha-1: Immune Modulation and the Sepsis Trial Result
Last updated 2026-09-13
Thymosin alpha-1, marketed as thymalfasin, is a 28-residue acetylated peptide originally isolated from thymosin fraction 5 of calf thymus. Around eight hundred and sixty results are indexed, making it one of the better-studied compounds in this catalogue. It is approved in a number of countries for specific indications, and a large randomised trial reported in 2025.
Mechanism
The described mechanism is modulation rather than stimulation. Reported actions include signalling through Toll-like receptors, particularly TLR9 and TLR2, on dendritic cells and monocytes, with downstream effects on cytokine production and on the maturation and differentiation of T lymphocytes.
The modulatory framing matters for interpretation. A compound reported to increase immune responsiveness in immunosuppressed states and to restrain it in hyperinflammatory ones is making a context-dependent claim, which is harder to test and easier to over-read than a simple agonist relationship.
Pica et al. (Expert Opin Biol Ther, 2018) report serum levels in normal and pathological conditions, which is a useful grounding paper because endogenous concentration ranges are rarely established for peptides in this catalogue.
Clinical literature
Wu et al. (Expert Opin Biol Ther, 2015) review treatment in chronic hepatitis B, historically the best-established indication. Matteucci et al. (Future Microbiol, 2017) cover HIV.
Wu et al. (BMJ, 2025) report TESTS, a multicentre, double-blinded, randomised, placebo-controlled phase 3 trial in sepsis. A trial of that design and scale published in a general medical journal is the highest-quality evidence available for any compound in this catalogue, and it should be read directly rather than through summaries.
Pei et al. (Expert Opin Biol Ther, 2018) had reviewed the sepsis question before that trial, which makes the pair useful for seeing how a randomised result revises a prior evidence base.
Recent context
Shehadeh et al. (J Infect Dis, 2023) report a pilot trial in hospitalised COVID-19 patients with hypoxaemia and lymphocytopenia. Pilot trials establish feasibility and generate estimates; they do not establish efficacy, and the paper is explicit about this.
Simonova et al. (Int J Mol Sci, 2025) address ageing and thymosin alpha-1, connecting the compound to thymic involution, which is the physiological rationale most often given for interest outside infectious disease.
Garaci et al. (Front Med, 2024) present it as a case study in phenotypic drug discovery, a useful framing given the compound was characterised functionally before its mechanism was understood.
Evidence assessment
Evidence base: the largest and highest-quality in this catalogue after the incretin compounds. Multiple approved indications and a 2025 randomised phase 3 sepsis trial. The modulatory mechanism is context-dependent and correspondingly harder to interpret than a simple agonist relationship.
Published literature
864 papers indexed on PubMed for Thymosin Alpha-1. Showing 12, reviews first.
- 01Aging and Thymosin Alpha-1
Simonova MA et al. · Int J Mol Sci · 2025
- 02Phenotypic drug discovery: a case for thymosin alpha-1
Garaci E et al. · Front Med (Lausanne) · 2024
- 03Thymosin alpha 1: A comprehensive review of the literature
Dominari A et al. · World J Virol · 2020
- 04Thymosin alpha 1 treatment for patients with sepsis
Pei F et al. · Expert Opin Biol Ther · 2018
- 05Serum thymosin alpha 1 levels in normal and pathological conditions
Pica F et al. · Expert Opin Biol Ther · 2018
- 06Thymosin alpha 1 and HIV-1: recent advances and future perspectives
Matteucci C et al. · Future Microbiol · 2017
- 07Immune Modulation with Thymosin Alpha 1 Treatment
King R, Tuthill C · Vitam Horm · 2016
- 08Thymosin alpha-1
Ancell CD et al. · Am J Health Syst Pharm · 2001
- 09Clinical applications of thymosin alpha-1
Goldstein AL · Cancer Invest · 1994
- 10
- 11
- 12Thymosin alpha-1 treatment in chronic hepatitis B
Wu X et al. · Expert Opin Biol Ther · 2015
Indexed from PubMed on 2026-07-19. Citations link to the source; we do not reproduce abstracts.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.